Continia®

Aflibercept is a recombinant fusion protein consisting of portions of the extracellular domains of human VEGF receptors 1 (VEGFR-1) and 2 (VEGFR-2), fused to the Fc portion of human immunoglobulin G (IgG1).

Aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.

Aflibercept acts as a soluble decoy receptor that binds VEGF-A (vascular endothelial growth factor A) and PlGF (placental growth factor) with higher affinity than their natural receptors, thereby inhibiting the binding and activation of these VEGF-related receptors. This suppresses the activation of VEGF-A receptors VEGFR-1 and VEGFR-2 on endothelial cell surfaces, reducing pathological neovascularization and excessive vascular permeability. Inhibition of PlGF activity, which exhibits synergy with VEGF-A, also contributes to decreased leukocyte infiltration and vascular inflammation.

Continia® is for intravitreal injection only. Intravitreal injections must be administered by a qualified physician experienced in such procedures, in accordance with medical standards and current guidelines, under adequate anesthesia and aseptic conditions.

Continia® is indicated for the treatment of retinal and posterior segment diseases characterized by neovascularization, subsequent fluid leakage, edema development, and dystrophic changes leading to vision loss.

GENERIUM is the first company in Russia to develop and manufacture a biosimilar of aflibercept.

Marketing Authorization No. 11113-(RG-RU)